|Trade names||Naphcon-a, Clear Eyes Red Relief, Visine A, others|
|Drug class||Alpha adrenergic agonist|
|Main uses||Stuffy nose, eye redness|
|Side effects||Burning, blurry vision|
|Nasal spray, eye drops|
|Chemical and physical data|
|Molar mass||210.274 g·mol−1|
|3D model (JSmol)|
Common side effects include blurry vision and stinging. Other side effects may include recurrence of stuffiness following stopping use, headache, palpitations, and nervousness. Safety in pregnancy is unclear. It works by activating alpha adrenergic receptor which cases small arteries to narrow.
It is used at a dose of 1 to 2 eye drops every 3 to 4 hours.
A few warnings and contraindications that apply to all naphazoline-containing substances intended for medicinal use are:
- Hypersensitivity to naphazoline
- Patients taking MAO inhibitors can experience a severe hypertensive crisis if given a sympathomimetic drug such as naphazoline HCl
- Use in infants and children can result in central nervous system depression, leading to coma and marked reduction in body temperature
- Should be used with caution in patients with severe cardiovascular disease including cardiac arrhythmia and in patients with diabetes, especially those with a tendency toward diabetic ketoacidosis
- Drug interactions can occur with anaesthetics that sensitize the myocardium to sympathomimetics (e.g. cyclopropane or halothane cautiously)
- Exercise caution when applying prior to use of phenylephrine.
- Extended use may cause rhinitis medicamentosa, a condition of rebound nasal congestion.
A possible association with stroke has been suggested.
Society and culture
- "Naphazoline Monograph for Professionals". Drugs.com. Archived from the original on 23 January 2021. Retrieved 11 November 2021.
- Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 552. ISBN 9783527607495. Archived from the original on 2016-12-29. Retrieved 2020-10-19.
- "Naphazoline ophthalmic Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 11 November 2021.
- Zavala JA, Pereira ER, Zétola VH, Teive HA, Nóvak EM, Werneck LC (September 2004). "Hemorrhagic stroke after naphazoline exposition: case report". Arquivos de Neuro-Psiquiatria. 62 (3B): 889–91. doi:10.1590/S0004-282X2004000500030. PMID 15476091.
- Green SM (2008). "Ophthalmology: Naphazoline". Tarascon Pocket Pharmacopoeia 2009. Jones and Bartlett. ISBN 978-0-7637-6572-9.